Developing Novel Therapies for Neuropsychiatric Diseases
We are building a pipeline that leverages the broad therapeutic potential of our lead product candidate, LB-102, for the treatment of schizophrenia and other neuropsychiatric diseases.
Learn MoreClinical ProgramsWe are a clinical-stage biopharmaceutical company developing novel therapies for the treatment of neuropsychiatric diseases.
Learn MorePipeline
We are building a pipeline that leverages the broad therapeutic potential of our lead product candidate, LB-102 beyond acute schizophrenia: potential to be developed as first in class benzamide long acting injectable and as treatment for bipolar depression and schizophrenia with predominantly negative symptoms
View Our PipelineFor Patients & Providers
We are evaluating the safety and efficacy of LB-102 in patients with acute schizophrenia.
Explore Our Clinical TrialsLB Pharma’s leading innovation
LB Pharma's lead asset and the foundation of the company's growth is LB-102, N-Methyl amisulpride. If approved by the FDA, LB-102 would be the first benzamide atypical approved to treat schizophrenia for the US market. We are also developing other US-market focused versions of life-saving drugs to treat CNS disorders that are available overseas but currently not approved by the FDA for marketing in the US.
READ MORE ABOUT LB-102
